EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.
Under the merger agreement, Channel will acquire 100% of Pelthos' issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under the ticker PTHS.
Also Read:
In connection with the transaction, Ligand has agreed to invest $18 million in the combined company, and the Investor Group has agreed to invest $32 million in a total of $50 million.
Upon completing the transaction, Scott Plesha, CEO of Pelthos, will become CEO of the combined company, and Frank Knuettel II, CEO of Channel Therapeutics, will become CFO. The transaction is expected to close in the summer of 2025.
The combined company will initially focus on accelerating the commercialization of Pelthos' Zelsuvmi (berdazimer) topical gel, 10.3%, for Molluscum contagiosum infections in adults and pediatric patients one year and older.
The U.S. Food and Drug Administration (FDA) approved Zelsuvmi in 2024. It is the first and only prescription therapy for molluscum infections approved for use at home by patients, parents, and caregivers.
Ligand is entitled to a 13% royalty on worldwide sales of Zelsuvmi.
The combined company will also retain Channel's existing NaV 1.7 development programs for various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
In December 2024, Channel Therapeutics announced that it achieved its endpoints in two pre-clinical in vivo models of the company's nerve block formulations for acute pain, showing material improvement in efficacy and duration over the existing standard of care, bupivacaine.
An update on the Channel's animal efficacy study for its eye pain program will be forthcoming.
'This transaction presents a compelling opportunity to launch a commercial-ready product, with significant financial backing from Murchinson, that has the potential to deliver both near and long-term value to our shareholders,' said Todd Davis, CEO of Ligand.
Frank Knuettel II, CEO of Channel Therapeutics, commented, 'We have performed extensive due diligence on the Zelsuvmi market opportunity and their team and operations, and we believe this is an extraordinary opportunity for current Channel shareholders. Strategically, it provides the potential for near-term revenue generation from an FDA-approved drug, the opportunity to advance Channel's existing NaV 1.7 programs, and expanded capitalization from strong, long-standing investors.'
Molluscum contagiosum is a poxvirus and one of the most common skin infections, afflicting an estimated 16.7 million people in the U.S.
Price Action: LGND stock is up 2.08% at $106.80 during the premarket session at the last check Thursday, and CHRO stock closed at $1.26 on Wednesday.
Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
LIGAND PHARMACEUTICALS (LGND): Free Stock Analysis Report
This article EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Airlines say AI won't set fares by passenger. Experts aren't so sure.
Cruising Altitude is a weekly column about air travel. Have a suggestion for a future topic? Fill out the form or email me at the address at the bottom of this page. It's no secret that airline pricing can be opaque and confusing to many travelers – even to experts. When I spoke to William J. McGee, senior fellow for aviation and travel at the American Economic Liberties Project, we joked that one of the worst questions an aviation expert can get asked at a party is, 'how do I find a good deal on airfare?' The answer is usually best represented by the shrugging emoji: ¯\_(ツ)_/¯ However, flight pricing is getting a renewed round of attention after Glen Hauenstein, president of Delta Air Lines, acknowledged on the company's earnings call last month that the airline is testing a new AI tool to help set its fares. Panic from consumers, advocates and even lawmakers naturally ensued as the specter of a new way for corporations to squeeze every penny out of us appeared on the horizon. For now, Delta (and other airlines) insist that they're not using AI to make prices truly individualized, but as technology gets more sophisticated, the already-dynamic pricing model used in the aviation industry is likely to get more granular. How do airlines price tickets today? Again, I say: ¯\_(ツ)_/¯ 'This is such an opaque process, there is so much that we don't know about what they know about us,' McGee said. Airlines acknowledge using some of our personal data in setting prices even now but say that such information is used only in the aggregate, not to tailor fares to individual travelers. In a letter to senators after last month's earnings call, Delta Air Lines' Executive Vice President of External Affairs, Peter Carter, explained how the carrier does and doesn't use passenger data for setting prices. 'There is no fare product Delta has ever used, is testing or plans to use that targets customers with individualized prices based on personal data. ... Our AI-powered pricing functionality is designed to enhance our existing fare pricing processes using aggregated data,' the letter said. 'Given the tens of millions of fares and hundreds of thousands of routes for sale at any given time, the use of new technology like AI promises to streamline the process by which we analyze existing data and the speed and scale at which we can respond to changing market dynamics.' Still, McGee said airlines have a history of testing the limits of price differentiation. 'It's really a much longer story going back 20 or 25 years at least. The technology has improved for them, and that has increased the airline industry's ability to tailor surveillance pricing, individualized pricing,' he said. For now, Delta says it's just using AI technology to streamline the work of its human analysts, who ultimately set and file its fares. Kyle Potter, editor of Thrifty Traveler, a travel and flight deal website, said it makes sense that airlines don't have the technical capability right now to target prices at specific passengers, because the system airlines use to file their fares relies on outdated technology. 'The technology in how airlines set fares and distribute them to their own website and other third-party sites, is really a roadblock to offering truly individualized airfare,' he said. 'There's no way to weave in the massive amount of data that airlines have or could have into offering a truly dynamic set of prices that varies from person to person. That's just not possible today at any kind of scale that I'm aware of.' How could AI be used for airline pricing in the future? For a third time I say: ¯\_(ツ)_/¯ There are just too many variables to be sure about how all this will develop. 'Where we're at right now is that we're going to come to look at Delta's comments last month to investors as a trial balloon for just how far Americans would be willing to go to accept some level of personalized pricing,' Potter said. 'The answer, at least for the last month, has pretty clearly been not at all.' Delta, which is the poster child for pricing developments in the airline world right now, insists it has no intention to ever set truly individualized prices. 'There is no fare product Delta has ever used, is testing or plans to use that targets customers with individualized prices based on personal data,' Carter's letter said. But McGee, who works as a consumer advocate, said it's important for both passengers and regulators to not get complacent as predictive pricing technology gets more powerful. 'It's going to be very hard, but it's necessary, for regulators and legislators to get their hands around this and understand it,' he said. 'It's not unimaginable that if this goes unchecked and there's not action by Congress or (the Department of Transportation), we may all be paying a different fare for the same flight within a few years. That's going to be a tough thing to undo.' Potter agreed with McGee's assessment. 'I think what we saw this year, what we've seen again and again and again over the last several decades is that airlines will do whatever it takes to charge people the highest fares possible within the constraints of the technology that they currently have,' he said. 'The global airline industry has been trying to push towards a future of personalized airfare. Just because there's a backlash now doesn't mean this isn't going to happen eventually.' Last week's Cruising Altitude: Travel tips every senior should know for stress-free flights How do I find the best airfares? For one final time, I say: ¯\_(ツ)_/¯ Airfares are subject to change at any time, and the prices are set by people working in a black box behind a curtain. In general, the advice experts have always given me is to trust your gut. If you feel like you're getting a good deal on airfare when you look for flights, you probably are. Also: it's a good idea to leverage consumer-facing price prediction tools, like those available on Google Flights, Expedia and other airfare aggregators. Zach Wichter is a travel reporter and writes the Cruising Altitude column for USA TODAY. He is based in New York and you can reach him at zwichter@ This article originally appeared on USA TODAY: Could AI make your plane ticket more expensive than your neighbor's?
Newsweek
8 minutes ago
- Newsweek
Nikki Haley: Trump Needs To Rebuild U.S.-India Relationship
In July 1982, President Ronald Reagan welcomed Indian Prime Minister Indira Gandhi to a state dinner at the White House. Toasting the friendship between our "two proud, free peoples," he said: "although our countries may travel separate paths from time to time, our destination remains the same." Four decades later, the U.S.-India relationship is at a troubling inflection point. To achieve the Trump administration's foreign policy goals—outcompeting China and achieving peace through strength—few objectives are more critical than getting U.S.-India relations back on track. The last few weeks have seen an explosive series of events. The Trump administration has threatened India with 25 percent tariffs for purchasing Russian oil, on top of the 25 percent President Donald Trump already slapped on Indian goods. These developments followed months of rising tension, including over the U.S. role in India-Pakistan ceasefire negotiations. Trump is right to target India's massive Russian oil purchases, which are helping to fund Vladimir Putin's brutal war against Ukraine. India has also traditionally been among the most protectionist economies in the world, with an average tariff rate more than five times the U.S. average in 2023. But India must be treated like the prized free and democratic partner that it is—not an adversary like China, which has thus far avoided sanctions for its Russian oil purchases, despite being one of Moscow's largest customers. If that disparity does not demand a closer look at U.S.-India relations, the realities of hard power should. Scuttling 25 years of momentum with the only country that can serve as a counterweight to Chinese dominance in Asia would be a strategic disaster. WASHINGTON, DC - MAY 22: Former U.N. Ambassador Nikki Haley announced that she would vote for former President Donald Trump during an event at the Hudson Institute on May 22, 2024 in Washington, DC. WASHINGTON, DC - MAY 22: Former U.N. Ambassador Nikki Haley announced that she would vote for former President Donald Trump during an event at the Hudson Institute on May 22, 2024 in Washington, the short term, India is essential in helping the United States move its critical supply chains away from China. While the Trump administration works to bring manufacturing back to our shores, India stands alone in its potential to manufacture at China-like scale for products that can't be quickly or efficiently produced here, like textiles, inexpensive phones, and solar panels. When it comes to defense, India's expanding military ties with the United States, Israel, and other American allies make it a crucial asset to the free world's security, and a rapidly growing market for U.S. defense equipment and cooperation. India's growing clout and security involvement in the Middle East could prove essential in helping to stabilize the region as America seeks to send fewer troops and dollars there. And India's location at the center of China's vital trade and energy flows could complicate Beijing's options in the case of a major conflict. In the longer term, India's significance is even more profound. Home to more than a sixth of humanity, India surpassed China as the world's most populous country in 2023, with a young workforce that contrasts with China's aging one. It is the world's fastest-growing major economy—soon to eclipse Japan as the world's fourth largest. India's rise represents the most significant geopolitical event since China's, and is among the greatest obstacles to China's goal of reshaping the global order. Simply put, China's ambitions will have to shrink as India's power grows. Yet, unlike Communist-controlled China, the rise of a democratic India does not threaten the free world. Partnership between the U.S. and India to counter China should be a no-brainer. India and China are unfriendly neighbors that have conflicting economic interests and ongoing territorial disputes, including a lethal skirmish over contested borders as recently as 2020. It would serve America's interests to help India stand up to its increasingly aggressive northern neighbor, both economically and militarily. And it would be a massive—and preventable—mistake to balloon a trade spat between the United States and India into an enduring rupture. If that were to happen, the Chinese Communist Party would be quick to play India and the United States against one another. For its part, India must take Trump's point over Russian oil seriously, and work with the White House to find a solution. As for the United States, the most urgent priority should be to reverse the downward spiral, which will require direct talks between President Trump and Prime Minister Narendra Modi. The sooner the better. The administration should focus on mending the rift with India and giving the relationship more high-level attention and resources—approaching what the U.S. devotes to China or Israel. Decades of friendship and good will between the world's two largest democracies provide a solid basis to move past the current turbulence. Navigating challenging issues like trade disagreements and Russian oil imports demand hard dialogue, but difficult conversations are often the sign of a deepening partnership. The United States should not lose sight of what matters most: our shared goals. To face China, the United States must have a friend in India. Nikki Haley, the Walter P. Stern Chair at the Hudson Institute, was US ambassador to the United Nations and governor of South Carolina. Bill Drexel is a fellow at the Hudson Institute. The views expressed in this article are the writers' own.
Yahoo
17 minutes ago
- Yahoo
Eli Lilly (LLY) Partners with Superluminal for AI Drug Discovery
Eli Lilly and Company (NYSE:LLY) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 14, Reuters reported that Eli Lilly and Company (NYSE:LLY) has entered into a deal worth $1.3 billion with Superluminal Medicines, a privately held company. The aim of this deal is to use AI to discover and develop small-molecule drugs for obesity and other cardiometabolic diseases. As per the report by Reuters, Eli Lilly and Company (NYSE:LLY) is already leading the obesity treatment market, which is expected to be worth $150 billion by the next decade. The company is looking to solidify its foothold in this area by developing next-generation drugs, making acquisitions, and entering into partnerships. The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates discovered with the help of Superluminal's proprietary AI-driven platform targeting G-protein-coupled receptors (GPCR). These proteins can influence physiological processes including metabolism, cell growth, and immune responses. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company focused on discovering, developing, and delivering innovative medicines. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 14 Best Aggressive Growth Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey.
